Comparative Pharmacology
Head-to-head clinical analysis: 8 HOUR BAYER versus SULINDAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: 8 HOUR BAYER versus SULINDAC.
8-HOUR BAYER vs SULINDAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting prostaglandin and thromboxane A2 synthesis, leading to analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis. Prodrug converted to active sulfide metabolite which inhibits COX enzymes.
325-650 mg every 8 hours for pain/fever; 81-325 mg daily for cardiovascular prophylaxis.
150-200 mg orally twice daily, with maximum daily dose 400 mg.
None Documented
None Documented
15-20 hours (terminal elimination half-life) for salicylate at therapeutic concentrations; prolonged to 20-30 hours at high doses due to saturation of hepatic metabolism (zero-order kinetics).
Clinical Note
moderateSulindac + Digitoxin
"Sulindac may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateSulindac + Deslanoside
"Sulindac may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateSulindac + Acetyldigitoxin
"Sulindac may decrease the cardiotoxic activities of Acetyldigitoxin."
Clinical Note
moderateSulindac + Ouabain
"Sulindac may decrease the cardiotoxic activities of Ouabain."
14 hours (sulfide active metabolite); 3-4 hours (parent sulindac). Steady-state attained in 3-4 days.
Renal excretion of conjugated salicylate metabolites (75% as salicyluric acid, 10% as salicyl phenolic glucuronide, 5% as salicyl acyl glucuronide, 5% as gentisic acid); 10% free salicylate; approximately 10% eliminated in feces via bile.
Primarily renal (about 50% as glucuronide conjugates, 25-30% as sulfide and sulfone metabolites); biliary/fecal elimination accounts for approximately 25-30%.
Category C
Category D/X
NSAID
NSAID